DD125699A5 - - Google Patents

Info

Publication number
DD125699A5
DD125699A5 DD193275A DD19327576A DD125699A5 DD 125699 A5 DD125699 A5 DD 125699A5 DD 193275 A DD193275 A DD 193275A DD 19327576 A DD19327576 A DD 19327576A DD 125699 A5 DD125699 A5 DD 125699A5
Authority
DD
German Democratic Republic
Application number
DD193275A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of DD125699A5 publication Critical patent/DD125699A5/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
DD193275A 1975-06-11 1976-06-09 DD125699A5 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2526373A DE2526373C2 (de) 1975-06-11 1975-06-11 Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden

Publications (1)

Publication Number Publication Date
DD125699A5 true DD125699A5 (enExample) 1977-05-11

Family

ID=5948981

Family Applications (1)

Application Number Title Priority Date Filing Date
DD193275A DD125699A5 (enExample) 1975-06-11 1976-06-09

Country Status (10)

Country Link
US (1) US4061661A (enExample)
JP (1) JPS51149260A (enExample)
CH (1) CH620452A5 (enExample)
DD (1) DD125699A5 (enExample)
DE (1) DE2526373C2 (enExample)
DK (1) DK137837C (enExample)
FR (1) FR2314197A1 (enExample)
GB (1) GB1554901A (enExample)
HU (1) HU174227B (enExample)
NL (1) NL7606137A (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2748442C3 (de) * 1977-10-26 1981-08-27 Schering Ag Berlin Und Bergkamen, 1000 Berlin 17α-(3-Jodbenzoyloxy)-9α -chlor4-pregnen-3.20-dione, Zwischenprodukte und Verfahren zu ihrer Herstellung, 9α -chlor-17α, 21-dihydroxy-1,4-pregnadien-3,20-dion und dieses enthaltende Arzneimittel
US4252729A (en) * 1978-05-12 1981-02-24 Hoffmann-La Roche Inc. Steroids and process for their manufacture
US4252719A (en) * 1978-08-17 1981-02-24 Research Corporation Steroid conversion method and products produced thereby
DE2929558C2 (de) * 1979-07-18 1982-03-11 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑ und/oder Δ↑1↑↑6↑ ungesättigten Steroiden
US4328162A (en) * 1980-09-05 1982-05-04 Eastman Kodak Company Process for preparing 9,11-unsaturated steroidal compound from the corresponding saturated steroidal compound
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
EP4717314A2 (en) 2011-10-14 2026-04-01 Sage Therapeutics, LLC 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
CN117304245A (zh) 2013-04-17 2023-12-29 萨奇治疗股份有限公司 刺激神经活性的19-去甲类固醇及其使用方法
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
CA2918735C (en) 2013-07-19 2023-08-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN105579043B (zh) 2013-08-23 2021-09-14 萨奇治疗股份有限公司 神经活性类固醇、组合物和其用途
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MY190408A (en) 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
US20170233433A1 (en) 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
LT3250210T (lt) 2015-01-26 2021-04-12 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti gydyti cns sutrikimus
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
EP3280420B1 (en) * 2015-04-10 2024-03-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CA3030420C (en) 2016-07-11 2025-11-18 Sage Therapeutics, Inc. C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
EP4606812A3 (en) * 2018-10-19 2025-10-15 Sage Therapeutics, Inc. 9(11)-unsaturated neuroactive steroids and their methods of use
EP3712161A1 (en) 2019-03-19 2020-09-23 Bionice, S.L.U. Process for preparing high puritiy allopregnanolone and intermediates thereof
JP7670626B2 (ja) 2019-05-31 2025-04-30 セージ セラピューティクス, インコーポレイテッド 神経刺激性ステロイド及びその組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2681353A (en) * 1952-03-11 1954-06-15 Sterling Drug Inc Chlorination of keto-steroids
GB1380248A (en) * 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy steroids and esters thereof

Also Published As

Publication number Publication date
HU174227B (hu) 1979-11-28
NL7606137A (nl) 1976-12-14
DE2526373C2 (de) 1983-11-10
JPS51149260A (en) 1976-12-22
CH620452A5 (enExample) 1980-11-28
FR2314197B1 (enExample) 1981-03-20
DK260976A (da) 1976-12-12
JPS6146480B2 (enExample) 1986-10-14
DK137837B (da) 1978-05-16
GB1554901A (en) 1979-10-31
DE2526373A1 (de) 1976-12-30
FR2314197A1 (fr) 1977-01-07
DK137837C (da) 1978-10-23
US4061661A (en) 1977-12-06

Similar Documents

Publication Publication Date Title
JPS51101561A (enExample)
JPS5333814B2 (enExample)
JPS5646432B2 (enExample)
JPS5545603Y2 (enExample)
JPS51140570U (enExample)
JPS5235252U (enExample)
FR2303211B1 (enExample)
JPS5441089B2 (enExample)
JPS5234990B2 (enExample)
JPS5273920U (enExample)
CH600083A5 (enExample)
CH601869A5 (enExample)
CH604633A5 (enExample)
CH601833A5 (enExample)
CH588401A5 (enExample)
CH604850A5 (enExample)
CH1020375A4 (enExample)
CH599497A5 (enExample)
BG23128A1 (enExample)
BG23337A1 (enExample)
CH597036A5 (enExample)
CH599019A5 (enExample)
BG22893A1 (enExample)
CH603499A5 (enExample)
BG21525A1 (enExample)

Legal Events

Date Code Title Description
EPE Extended patent has ceased